Journey Medical Corporation develops, sells and markets FDA-approved prescription pharmaceutical products for dermatological conditions. The company is a commercial-stage dermatology pharmaceutical issuer with a portfolio of branded prescription drugs marketed in the United States.
Recurring news for DERM centers on quarterly and annual financial results, corporate updates, and commercialization progress across its dermatology portfolio. Company updates frequently discuss Emrosi™, a modified-release minocycline product approved for inflammatory lesions of rosacea in adults, including payer access, group purchasing organization contracts, prescription demand, product revenue, and clinical data presentations or publications for Emrosi/DFD-29.
Journey Medical Corporation has launched an initial public offering (IPO) of 3,200,000 shares of common stock, expected to price between $10 and $12 per share. The company, a subsidiary of Fortress Biotech (FBIO), may also allow underwriters to purchase an additional 480,000 shares. Journey Medical aims to list its shares on The Nasdaq Capital Market under the symbol ‘DERM.’ B. Riley Securities is the sole book-running manager, with Roth Capital Partners as a co-manager. The offering is subject to market conditions and regulatory approval.